PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29695239-0	2018	Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-kappaB activity.	Cytarabine	20-30	Spi-B transcription factor	Homo sapiens	120-124	
29695239-12	2018	CONCLUSION: We show that cytarabine resistance potentially can be avoided or at least delayed through co-treatment with bortezomib, and that down-regulation of dCK and up-regulation of SPIB and NF-kappaB are the main molecular events driving cytarabine resistance development.	Cytarabine	242-252	Spi-B transcription factor	Homo sapiens	185-189